NEW YORK (GenomeWeb) – Abbott reported on Wednesday morning that its first quarter diagnostic revenues decreased around 2 percent year over year, although its molecular diagnostic sales inched up a fraction of a percent.

The Abbott Park, Ill.-based company reported total worldwide revenues of $4.90 billion for the three months ended March 31, up 3 percent from $4.76 billion a year ago and surpassing analysts' consensus estimate of $4.85 billion. Excluding negative currency effects, total sales increased 10 percent year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.